Outset Medical announces CEO Leslie Trigg's presentation at J.P. Morgan Healthcare conference on January 14, 2026.
Quiver AI Summary
Outset Medical, Inc. announced that its Chair and CEO, Leslie Trigg, will present at the upcoming J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will focus on Outset's innovative technology aimed at reducing the cost and complexity of dialysis, specifically featuring the Tablo® Hemodialysis System. This FDA-cleared system integrates water purification and on-demand dialysate production for use in various healthcare settings, from hospitals to home care. Trusted by over 1,000 healthcare facilities, Tablo enables healthcare providers to create in-house dialysis programs, enhancing operational and clinical outcomes. The live and archived webcast of the presentation will be accessible on the company's website.
Potential Positives
- Outset Medical is showcasing its innovative technology at a prestigious event, the J.P. Morgan Healthcare conference, highlighting the company's role as a leader in medical technology.
- The Tablo® Hemodialysis System is already trusted by over 1,000 U.S. healthcare facilities, indicating strong market acceptance and potential for growth.
- The company's integrated approach to dialysis, combining water purification and dialysate production, positions Outset Medical as a differentiated player in the healthcare market, aiming to improve operational, clinical, and financial outcomes for providers.
- Outset's commitment to transforming kidney care reflects a dedication to innovation and improving patient lives, which may enhance its reputation and attract further investment or partnerships.
Potential Negatives
- None
FAQ
When will Outset Medical present at the J.P. Morgan Healthcare conference?
Outset Medical will present on Wednesday, January 14, 2026, at 4:30 p.m. Pacific time.
How can I access Outset Medical's presentation?
A live and archived webcast of the presentation will be available in the "Investors" section of Outset Medical's website.
What is the main technology developed by Outset Medical?
Outset Medical developed the Tablo® Hemodialysis System, designed to reduce the cost and complexity of dialysis.
How many healthcare facilities use Outset Medical's technology?
More than 1,000 U.S. healthcare facilities trust Outset Medical's technology for dialysis treatments.
What is the mission of Outset Medical?
Outset Medical aims to transform kidney care through innovation and improving the lives of patients and healthcare professionals.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OM Insider Trading Activity
$OM insiders have traded $OM stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $OM stock by insiders over the last 6 months:
- LESLIE TRIGG (Chair and CEO) has made 0 purchases and 2 sales selling 1,820 shares for an estimated $15,857.
- KAREN DREXLER sold 1,548 shares for an estimated $6,764
- JOHN L. BROTTEM (General Counsel) has made 0 purchases and 2 sales selling 771 shares for an estimated $6,717.
- MARC NASH (EVP Operations R&D & Service) has made 0 purchases and 2 sales selling 490 shares for an estimated $4,266.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OM Revenue
$OM had revenues of $29.4M in Q3 2025. This is an increase of 2.67% from the same period in the prior year.
You can track OM financials on Quiver Quantitative's OM stock page.
$OM Hedge Fund Activity
We have seen 47 institutional investors add shares of $OM stock to their portfolio, and 45 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,621,137 shares (-99.9%) from their portfolio in Q3 2025, for an estimated $22,890,454
- DURABLE CAPITAL PARTNERS LP removed 633,420 shares (-38.2%) from their portfolio in Q3 2025, for an estimated $8,943,890
- PURA VIDA INVESTMENTS, LLC removed 424,120 shares (-98.8%) from their portfolio in Q3 2025, for an estimated $5,988,574
- MORGAN STANLEY added 311,805 shares (+256.9%) to their portfolio in Q3 2025, for an estimated $4,402,686
- BLACKROCK, INC. added 265,065 shares (+26.9%) to their portfolio in Q3 2025, for an estimated $3,742,717
- MILLENNIUM MANAGEMENT LLC added 262,874 shares (+165.8%) to their portfolio in Q3 2025, for an estimated $3,711,780
- ALYESKA INVESTMENT GROUP, L.P. added 150,000 shares (+10.2%) to their portfolio in Q3 2025, for an estimated $2,118,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OM Analyst Ratings
Wall Street analysts have issued reports on $OM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 12/16/2025
To track analyst ratings and price targets for $OM, check out Quiver Quantitative's $OM forecast page.
$OM Price Targets
Multiple analysts have issued price targets for $OM recently. We have seen 3 analysts offer price targets for $OM in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Marie Thibault from BTIG set a target price of $17.0 on 12/16/2025
- Rick Wise from Stifel set a target price of $14.0 on 11/11/2025
- Shagun Singh from RBC Capital set a target price of $17.0 on 11/11/2025
Full Release
SAN JOSE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that Chair & CEO Leslie Trigg will present at the 44 th annual J.P. Morgan Healthcare conference on Wednesday, January 14, 2026, at 4:30 p.m. Pacific time.
A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/ .
About Outset Medical, Inc.
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit
www.outsetmedical.com
.
Contact
Jim Mazzola
Vice President, Investor Relations
[email protected]
